PCSA (Processa Pharmaceuticals) Shiller PE Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PCSA Processa Pharmaceuticals Inc PCSA
29 GF Score
Price $2.61
! 1 Warning Sign
View Full Analysis

What is Processa Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Processa Pharmaceuticals  (NAS:PCSA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Processa Pharmaceuticals Shiller PE Ratio Related Terms


Processa Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Processa Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals Shiller PE Ratio Chart

Processa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Processa Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PCSA vs BOLT, BRTX, LIMN: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Processa Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Processa Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Processa Pharmaceuticals's Shiller PE Ratio falls into.


PCSA
29GF Score
Processa Pharmaceuticals Inc PCSA
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Processa Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Processa Pharmaceuticals's E10 for the quarter that ended in Mar. 2026 is calculated as:

For example, Processa Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.29/330.2130*330.2130
=-1.290

Current CPI (Mar. 2026) = 330.2130.

Processa Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201606 -245.000 241.018 -335.669
201609 -245.000 241.428 -335.099
201612 -226.388 241.432 -309.637
201703 -245.000 243.801 -331.837
201706 -119.281 244.955 -160.797
201709 -490.001 246.819 -655.560
201712 -152.171 246.524 -203.829
201803 -105.000 249.554 -138.937
201806 -105.000 251.989 -137.595
201809 -70.000 252.439 -91.566
201812 -40.000 251.233 -52.575
201903 -70.000 254.202 -90.931
201906 -90.000 256.143 -116.026
201909 -80.000 256.759 -102.887
201912 -115.000 256.974 -147.776
202003 -80.000 258.115 -102.346
202006 -65.000 257.797 -83.259
202009 -275.000 260.280 -348.888
202012 -506.104 260.474 -641.608
202103 -70.000 264.877 -87.267
202106 -100.000 271.696 -121.538
202109 -95.000 274.310 -114.361
202112 -105.000 278.802 -124.362
202203 -100.000 287.504 -114.855
202206 -160.000 296.311 -178.306
202209 -185.000 296.808 -205.821
202212 -401.250 296.797 -446.426
202303 -88.250 301.836 -96.547
202306 -48.500 305.109 -52.491
202309 -38.500 307.789 -41.305
202312 -41.750 306.746 -44.944
202403 -27.750 312.332 -29.339
202406 -25.250 314.175 -26.539
202409 -25.750 315.301 -26.968
202412 -18.530 315.605 -19.388
202503 -7.580 319.799 -7.827
202506 -6.250 322.561 -6.398
202509 -1.750 324.800 -1.779
202512 -1.306 324.054 -1.331
202603 -1.290 330.213 -1.290

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Processa Pharmaceuticals Business Description

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
29GF Score

Get the complete analysis for PCSA

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.61
Price